FDA Clears Fate Therapeutics’ Dual-Target CAR-T FT839 for Autoimmune Diseases
Following positive FT819 data in systemic sclerosis, the company now targets multiple autoimmune indications.
/ 2 items
Following positive FT819 data in systemic sclerosis, the company now targets multiple autoimmune indications.
Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.